ANDA 78170, held by Glenmark Pharms Ltd. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 78170 (Metformin Hydrochloride), held by Glenmark Pharms Ltd, was first approved by FDA on May 23, 2008, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 23, 2008 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet;oral | Metformin Hydrochloride | Discontinued |
| Metformin Hydrochloride850MG · tablet;oral | Metformin Hydrochloride | Discontinued |
| Metformin Hydrochloride1GM · tablet;oral | Metformin Hydrochloride | Discontinued |
| Aug 11, 2026 | Supplement 22Labeling · Standard review | Approved | None posted |
| Dec 11, 2012 | Supplement 5Labeling | Approved | None posted |
| May 20, 2010 | Supplement 6Labeling | Approved | None posted |
| Feb 25, 2010 | Supplement 14Labeling | Approved | None posted |
| Jan 27, 2010 | Supplement 15Labeling | Approved | None posted |
| May 23, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters